Efavirenz is a substrate and in turn modulates the expression of the efflux transporter ABCG2/BCRP in the gastrointestinal tract of the rat (Q84624581)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21803024%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Efavirenz is a substrate and in turn modulates the expression of the efflux transporter ABCG2/BCRP in the gastrointestinal tract of the rat (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21803024%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

Christian Hocht

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21803024%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Alejandro Sosnik

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21803024

8 December 2024

Roxana N. Peroni

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21803024

8 December 2024

Stefania S. Di Gennaro

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21803024

8 December 2024

Christian Hocht

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21803024

8 December 2024

Diego A. Chiappetta

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21803024

8 December 2024

Modesto C. Rubio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21803024

8 December 2024

Guillermo F. Bramuglia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21803024

8 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21803024

8 December 2024

publication date

23 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21803024%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

9 February 2020

https://api.elsevier.com/content/article/PII:S0006295211005399?httpAccept=text/xml

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

https://api.elsevier.com/content/article/PII:S0006295211005399?httpAccept=text/plain

8 December 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

8 December 2024

published in

Biochemical Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21803024%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21803024%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21803024%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

1227-1233

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21803024%20AND%20SRC:MED&resulttype=core&format=json

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

[Pharmaceutical care program for pediatric patients receiving antiretroviral therapy]

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Higher efavirenz plasma levels correlate with development of insomnia

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Electronic and resonance effects on the ionization of structural analogues of efavirenz

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz).

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected].

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Efavirenz in the therapy of HIV infection.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Paradoxically elevated efavirenz concentrations in HIV/tuberculosis- coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Modulation of human BCRP (ABCG2) activity by anti-HIV drugs

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Induction of multiple drug transporters by efavirenz

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Protein measurement with the Folin phenol reagent

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Acetaminophen-induced stimulation of MDR1 expression and activity in rat intestine and in LS 174T human intestinal cell line

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.BCP.2011.07.081

8 December 2024

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21803024%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21803024%20AND%20SRC:MED&resulttype=core&format=json